Figure 1.

Identification of JMJD1C as a novel NFE2 target gene. (A) NFE2 binding to the JMJD1C locus. Top: schematic representation of potential binding sites at the JMJD1C locus determined by in silico analysis.⁸ Bottom: HEL cell lysates were chromatin immunoprecipitated with antibodies against NFE2 or an IgG control. PCR was performed with primers flanking the 3 predicted binding sites as well as on control sites at +3.2 kb in the NFE2 gene and in the myogenin locus. Data are representative of 3 independent experiments. (B) Jmjd1c mRNA expression in NFE2tg mice. RNA was isolated from bone marrow cells of wild-type (wt) and hNFE2tg mice⁴ and subjected to quantitative RT-PCR for Jmjd1c expression. Expression levels were normalized to mB2M expression. Bars represent the mean. ***P < .001 by the Student t test. (C) Jmjd1c mRNA levels upon expression in CB3 cells. CB3 cells were transfected with pLego-iG-NFE2wt or an empty control vector and sorted for GFP positivity. Jmjd1c expression was quantified as described in panel B. Mean values and standard error of the mean (SEM) are shown. *P < .05 by the Student t test.